Unlike VERO and MDCK cells, neither CEK cells nor HepaLife's PBS-1 require the need for exogenous proteases, such as Trypsin, therefore eliminating an additional step in manufacturing. However, unlike CEK cells, the PBS-1 cell line is less prone to dangerous contaminating pathogens which are undesirable, disease-causing micro-organisms.
"Our patented PBS-1 cell line successfully produces more influenza virus at higher concentrations than any other tested cell lines, and is able to eliminate a cumbersome manufacturing step involving exogenous proteases," explained Mr. Menzler. "Our cell line is able to remain free of unwanted pathogens, and above all, can out-live and outperform the only other tested cell line that registered any evident influenza virus levels, the CEK."
CEK cells are a primary cell line, typically unable to survive beyond five generations of growth, or 'passages'. HepaLife's PBS-1 cells are a continuous cell line which has already successfully lived through hundreds of passages.
Importantly, scientists have discovered that the PBS-1 cell line may also be suitable for isolating the influenza virus from respiratory samples for diagnostic testing. According to research findings, nineteen blind influenza virus received from human respiratory samples were successfully identified as type-A influenza using PBS-1 cells.
Entitled "High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases," this new data was presented by Kristen Smith from Michigan State University, Department of Animal Science, Molecular Pathogenesis Laboratory, East Lansing, Michigan.
"The success of our patented PBS-1 cell line for influenza
vaccine production alongside the parallel success of our patented
PICM-19 cell line for development of the world's first-of-its-kind
artificial liver device, clearly establishes HepaLife's position as